Orchestra BioMed Holdings, Inc. — Form 10-Q
Filed August 10, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 18/100
What the filing says
Orchestra BioMed Holdings, Inc. adopted a new 2026 Employee Stock Purchase Plan (approved by stockholders June 23, 2026, effective upon board adoption April 22, 2026) authorizing up to 750,000 shares of common stock for employee purchase. The plan features two components: a tax-qualified 423 Component and a Non-423 Component, with purchase prices set at 85% of fair market value on the offering date or purchase date (whichever is lower), and no specific financial commitment or impact disclosed in the filing.
Why this rating
Routine ESPP adoption—standard employee compensation governance. 750K shares at ~$63.4M market cap ≈ modest dilution; no immediate cash outlay or material liability. Administrative disclosure.
See more from August 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.